Careers
|
Partnerships
|
Contact
|
Login
Response Biomedical logo

Examining clinical benefits of Troponin I, in adult and pediatric patients

Insights for Enhanced Patient Care and Diagnosis
52 min
In this webinar, Dr. Lizeth Castelblanco and Dr. Andres Florez will explore the utility of Troponin I in two distinct medical specialties: pediatrics and adult medicine. The speakers will delve into the significance of this cardiac marker within these specialties, offering insights from a comprehensive examination of various articles, the latest international cardiology guidelines, suggested algorithms, and a series of case studies.
Key Learning Objectives:
  • Explanation that Troponin I elevation does not solely indicate Acute Myocardial Infarction (AMI).
  • Examination of the different types of available tests.
  • Review of the Acute Coronary Syndrome management algorithm as per the guidelines of the European Society of Cardiology.
  • Discussion on the role of Troponin I in Point-of-Care Testing (POCT) environments.
  • Benefits associated with utilizing Troponin I as a diagnostic tool.

Contact Our Specialists

24 hour Technical Support available to all RAMP Customers

Faster

Improves turnaround time
for faster triage

Accurate

Provides high quality results
with built in QC

Reliable

Enables clinicians to make
informed decisions
©2025 Response Biomedical. All Rights reserved

You will be able to participate in this research study if you are:

  • 18 years of age or older.
  • In good health.
  • Willing to voluntarily agree to sign the consent form.

You will not be able to participate in this research study if:

  • You are considered/consider yourself to be a vulnerable subject (e.g., nursing home residents, institutionalized persons, pregnant and nursing women, children under the age of 19, prisoners, or persons with decisional incapacity).
  • You are currently diagnosed with, or have a history of, underlying major medical conditions (for example: heart disease, hypertension, stroke, renal disease, diabetes and bleeding disorders).
  • You are actively in hemodialysis treatment.
  • You have been told that you have HIV, chronic active hepatitis B, or chronic, active hepatitis C.
  • You have been hospitalized (for more than 24 hours) in the past three months.
  • You are actively receiving treatment or monitoring for certain cancers (excluding non-melanoma skin cancers and localized prostate cancer not requiring systemic therapy).
  • You are already enrolled in this study.
  • You are unable and/or unwilling to provide informed consent.
If you are interested in participating in this study, you can schedule a time to virtually meet with the clinical team at Response Biomedical. During your online meeting, Response Biomedical will send you a self-assessment questionnaire via DocuSign to determine eligibility. If you are eligbile to participate, a team member will explain the study in detail, review the consent form with you, and send the consent form to you for electronic signature. Once you have signed the consent form, the study staff will arrange an appointment for you at a nearby LifeLabs location.

To participate in this study at a LifeLabs location, you will need to be able to print a paper copy of the requisition to take with you to your appointment. If you do not have access to a printer but would still like to participate, you can book an appointment at the Response Biomedical location or attend a community collection event.
At your LifeLabs appointment, a trained LifeLabs professional will collect two (2) 4 mL tubes of whole blood—approximately two teaspoons.
After collection, your blood sample will be sent to Response Biomedical, where a trained operator will use it to perform the RAMP® hs-TnI test.

Book A Demo

"*" indicates required fields

Name*

Meet Us at the Event

"*" indicates required fields

Name*

Technical Support

"*" indicates required fields

Name*

Get A Quote

"*" indicates required fields

Name*

Partnership

"*" indicates required fields

Name*

You will be able to participate in this research study if you are:

  • 18 years of age or older.
  • In good health.
  • Willing to voluntarily agree to sign the consent form.

You will not be able to participate in this research study if:

  • You are considered/consider yourself to be a vulnerable subject (e.g., nursing home residents, institutionalized persons, pregnant and nursing women, children under the age of 19, prisoners, or persons with decisional incapacity).
  • You are currently diagnosed with, or have a history of, underlying major medical conditions (for example: heart disease, hypertension, stroke, renal disease, diabetes and bleeding disorders).
  • You are actively in hemodialysis treatment.
  • You have been told that you have HIV, chronic active hepatitis B, or chronic, active hepatitis C.
  • You have been hospitalized (for more than 24 hours) in the past three months.
  • You are actively receiving treatment or monitoring for certain cancers (excluding non-melanoma skin cancers and localized prostate cancer not requiring systemic therapy).
  • You are already enrolled in this study.
  • You are unable and/or unwilling to provide informed consent.
If you agree to take part in this study, study staff will discuss a consent form with you. After you sign the consent form, a phlebotomist will collect a blood sample from you. This will include two (2) 4mL tubes worth of whole blood, which is slightly less than 2 teaspoons. Once the blood has been collected, a trained operator will use your blood sample to perform the RAMP® hs-TnI test. The entire visit should last around 30 minutes.Â